RPN-001 is a novel orally administered aromatase inhibitor being developed for the treatment of infertility in men with low serum testosteroneNo FDA-approved oral therapies currently exist for this ...

Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced eight abstracts from its novel clinical development programs, including oral presentations featuring its lead investigational drug ...

Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to ...

A new cancer drug candidate developed by Lawrence Livermore National Laboratory, BridgeBio Oncology Therapeutics and ...

Insilico Medicine, a clinical-stage biotechnology company driven by generative artificial intelligence (AI), today announces that the first patient has been dosed in a global multicenter clinical ...

The firm is also considering a US regulatory submission of its QiAcuityDx system along with a companion diagnostic test.

The biotech sector remains one of the most dynamic areas of the market, driven by clinical breakthroughs, regulatory ...

A new cancer drug candidate has demonstrated the ability to block tumor growth without triggering a common and debilitating ...

The urgent need for effective vaccines has prompted vaccine developers to pivot towards COVID-19, resulting in rapid growth of preclinical candidates and an accelerated vaccine development pipeline. 1 ...

Ocugen, Inc. Announces U.S. FDA Clearance of Investigational New Drug Amendment to Initiate Phase 2/3 Pivotal Confirmatory Clinical Trial of OCU410ST—Modifier Gene Therapy Candidate for ...

The following is a summary of “Mixed Autoimmune Hemolytic Anemia: A Systematic Review of Epidemiology, Clinical Characteristics, Therapies, and Outcomes,” published in the May 2025 issue of American ...